Table 1.
Patient demographics and clinical characteristics
| n=3120 | |
| Age (years), mean (SD) (n=3117*) | 53.1 (14.0) |
| Sex, n (%) | |
| Male | 1037 (33.2) |
| Female | 2083 (66.8) |
| BMI, mean (SD) | 25.5 (4.1) |
| Physician-perceived disease activity, n (%) | |
| Remission (DAS28 <2.6) | 1327 (42.5) |
| Low (DAS28 2.6–3.2) | 1063 (34.1) |
| Moderate (DAS28 3.2–5.1) | 613 (19.6) |
| High (DAS28 >5.1) | 117 (3.8) |
| Physician-perceived pain, n (%) | |
| None | 770 (24.7) |
| Mild | 1517 (48.6) |
| Moderate | 690 (22.1) |
| Severe | 125 (4.0) |
| Don’t know | 18 (0.6) |
| No of tender joints, mean (SD) (n=1451) | 7.2 (6.4) |
| No of swollen joints, mean (SD) (n=810) | 5.6 (5.1) |
| Time since diagnosis (years), mean (SD) (n=2643) | 7.3 (7.2) |
| Currently receiving glucocorticoid, n (%) | 754 (24.2) |
| Currently receiving low dose glucocorticoid, n (%) | 687 (22.0) |
| Currently receiving high dose glucocorticoid, n (%) | 67 (2.1) |
| Currently receiving csDMARD, n (%) | 1884 (60.4) |
| Currently receiving methotrexate, n (%) | 1611 (51.6) |
| Currently receiving advanced therapy, n (%) | 2142 (68.7) |
*n=3 patients classified as >90 years old, excluded from mean patient age.
BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, Disease Activity Score-28; SD, standard deviation.